![]() |
市場調查報告書
商品編碼
1930056
全球細胞培養基市場:市場規模、佔有率、成長率、產業分析、按類型、應用和地區劃分的考慮因素以及未來預測(2025-2034)Cell Culture Media Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034 |
||||||
預計2025年全球細胞培養基市場規模將達30.2億美元,2026年將達33.9億美元。預計2034年將進一步成長至98.6億美元,預測期內複合年增長率(CAGR)為14.27%。北美市場在2025年將佔43.61%的市場佔有率,這得益於其強大的生物製藥研發基礎設施、疫苗生產能力以及美國主要行業參與者的高度集中。傳染病日益普遍促使疫苗需求快速成長,這是推動該地區市場成長的關鍵因素。
細胞培養基是含有促進細胞和微生物生長、維持和保存必需營養物質的固體、液體或半固體製劑。這些產品在生物製藥生產中至關重要,支持疫苗生產、基因治療和再生醫學應用。由於疫苗研發和全球生產設施的擴張,COVID-19 大流行顯著增加了對細胞培養基的需求。
主要市場驅動因子
疫苗生產和生物製藥研發的擴張:製藥公司加大對疫苗研發的投資正在推動市場成長。例如,富士膠片灣科學公司在北卡羅來納州投資 1.88 億美元,用於擴建其細胞培養基生產設施。幹細胞療法、再生醫學和個人化療法研發的增加進一步推動了對高品質培養基的需求。
先進細胞培養技術的應用:重組白蛋白補充劑、奈米纖維培養基和3D細胞培養平台等創新技術正在改善細胞生長、生產力和即時分析。默克集團的奈米纖維培養皿和沃特世公司的BioAccord LC-MS與Andrew+機器人聯用等技術,能夠更有效率地進行藥物和培養基測試,進而促進細胞生長。
基因治療和腫瘤研究的應用:細胞培養基對於基因治療中病毒載體的擴增和癌症研究中的細胞培養至關重要。 OptiPEAK等平台可支持HEK293t細胞的生長,用於臨床和商業生產。基因治療和癌症研究在全球範圍內的日益普及也推動了培養基的廣泛應用。
市場限制因子
新興國家缺乏實驗室基礎設施和熟練專業人員等挑戰。中低收入國家往往實驗室設施不足,且缺乏訓練有素的技術人員,導致品質和污染問題。此外,發展中國家對動物性成分的倫理擔憂以及研發投入有限,進一步限制了市場成長。
市場區隔
依類型:市場細分為傳統培養基、特殊培養基、無血清培養基和其他培養基。截至2024年,傳統培養基因其在基因工程、研發和基礎生物學研究中的廣泛應用而佔市場主導地位。特殊培養基和無血清培養基因其在疫苗生產、單株抗體製造和細胞治療的應用而呈現顯著增長。
按應用:應用包括藥物篩選和開發、研究和其他。藥物篩選和開發是一個主要細分市場,其成長動力來自疫苗開發和用於藥物測試的模擬人體生理的3D細胞培養模型。由於幹細胞研究、癌症研究和先進治療性生物製劑的開發,研究領域正在迅速擴張。
按最終用戶劃分:生物技術和製藥行業引領市場,這主要得益於疫苗和細胞療法監管審批的不斷增加。由於全球研究項目的增多,研究實驗室的市場佔有率也不斷擴大。
預計北美市場將在2025年達到13.2億美元,並在2026年增長至13.8億美元,這主要得益於對生物製藥研發和疫苗生產基礎設施的支持。歐洲市場預計將穩定成長,這主要得益於賽多利斯公司等企業的策略擴張以及對先進療法的強有力的監管支持。亞太地區預計將實現最高的複合年增長率,這主要得益於生物製藥研究、疫苗生產和幹細胞計畫的快速成長。日本、中國和印度將是該地區市場擴張的主要貢獻者。
The global cell culture media market was valued at USD 3.02 billion in 2025 and is projected to reach USD 3.39 billion in 2026, eventually growing to USD 9.86 billion by 2034, reflecting a CAGR of 14.27% during the forecast period. North America dominated the market in 2025 with a 43.61% share, driven by strong biopharmaceutical research infrastructure, vaccine manufacturing capabilities, and a high concentration of key industry players in the U.S. The rapid demand for vaccines due to increasing prevalence of infectious diseases is a major factor propelling growth in the region.
Cell culture media are solid, liquid, or semi-solid formulations containing essential nutrients that simulate the growth, propagation, maintenance, and storage of cells and microorganisms. These products are critical in biopharmaceutical manufacturing, supporting vaccine production, gene therapies, and regenerative medicine applications. The COVID-19 pandemic significantly increased demand for cell culture media due to vaccine development and expansion of production facilities globally.
Key Market Drivers
Expansion of Vaccine Production and Biopharmaceutical R&D: Increasing investments by pharmaceutical companies in vaccine research and development are driving market growth. For instance, FUJIFILM Irvine Scientific invested USD 188 million in North Carolina to expand production facilities for cell culture media. Rising research into stem cell therapies, regenerative medicine, and personalized treatments is further boosting demand for high-quality culture media.
Adoption of Advanced Cell Culture Technologies: Innovations, such as recombinant albumin supplements, nano-fiber media, and 3D cell culture platforms, are improving cell growth, productivity, and real-time analysis. Technologies like Merck KGaA's nanofiber culture dishes and Waters Corporation's BioAccord LC-MS combined with Andrew+ robots facilitate more efficient drug and media testing, supporting growth.
Applications in Gene Therapies and Oncology Research: Cell culture media are essential for viral vector propagation in gene therapy and for culturing cells in cancer research. Platforms like OptiPEAK support the expansion of HEK293t cells for clinical and commercial manufacturing. Increasing gene therapy applications and cancer research initiatives globally have augmented the adoption of culture media.
Market Restraints
The market faces challenges such as insufficient laboratory infrastructure and shortage of skilled professionals in emerging nations. Low- and middle-income countries often have poorly equipped labs and lack well-trained technicians, leading to quality and contamination concerns. Ethical concerns around animal-derived components and limited R&D investments in developing countries further constrain market growth.
Market Segmentation
By Type: The market is segmented into classical media, specialty media, serum-free media, and others. Classical media dominated the market in 2024 due to extensive applications in genetic engineering, R&D, and basic biological studies. Specialty and serum-free media are witnessing strong growth due to applications in vaccine production, monoclonal antibody manufacturing, and cell therapy.
By Application: The applications include drug screening and development, research, and others. Drug screening and development is a key segment, propelled by vaccine development and 3D cell culture models that replicate human physiology for drug testing. The research segment is expanding rapidly due to stem cell studies, cancer research, and development of advanced therapeutic biologics.
By End-User: Biotechnology and pharmaceutical industries dominate the market, driven by increasing regulatory approvals for vaccines and cell-based therapies. Academic and research laboratories are also expanding their share due to the rise in global research projects.
North America had a market size of USD 1.32 billion in 2025, increasing to USD 1.38 billion in 2026, supported by biopharmaceutical R&D and vaccine manufacturing infrastructure. Europe is growing steadily due to strategic expansions by companies such as Sartorius AG and strong regulatory support for advanced therapies. Asia Pacific is projected to witness the highest CAGR, driven by rapid growth in biopharmaceutical research, vaccine production, and stem cell initiatives. Japan, China, and India are key contributors to the regional expansion.
Competitive Landscape
The market is dominated by Thermo Fisher Scientific, Danaher, FUJIFILM Irvine Scientific, BD, Merck KGaA, Sartorius AG, Corning, PromoCell, and Lonza. Key strategies include product launches, capacity expansions, mergers, acquisitions, and collaborations. For example, Lonza launched the TheraPro CHO media system in 2023, and Thermo Fisher expanded its dry powder media facility in New York in 2022 to meet global demand.
Conclusion
The global cell culture media market is poised for significant growth from 2025 to 2034, driven by increasing demand for vaccines, expansion of biopharmaceutical R&D, adoption of advanced cell culture technologies, and growing applications in gene therapy and oncology research. North America leads the market, while Asia Pacific offers the fastest growth potential. Classical media, drug screening applications, and biotechnology and pharmaceutical end-users are expected to maintain dominance. Strategic initiatives by major players and technological innovations will continue to drive market expansion, reaching USD 9.86 billion by 2034 and supporting the development of next-generation therapeutics and vaccines worldwide.
Segmentation By Type
By Application
By End User
By Region